deltatrials
Completed OBSERVATIONAL NCT03624803

DAPA - Egypt Study

Usage of Dapagliflozin - a Sodium Glucose Co-transporter Inhibitor, in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Egyptian Patients

Sponsor: AstraZeneca

Conditions Type-2 Diabetes
Updated 20 times since 2018 Last updated: Feb 8, 2021 Started: Mar 9, 2019 Primary completion: Mar 30, 2020 Completion: Mar 30, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03624803, this observational or N/A phase trial focuses on Type-2 Diabetes and remains completed. Sponsored by AstraZeneca, it has been updated 20 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jul 2024 · 40 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Mar 2021 — Jul 2024 [monthly]

    Completed

  5. Jan 2021 — Mar 2021 [monthly]

    Completed

▶ Show 15 earlier versions

  1. Jul 2020 — Jan 2021 [monthly]

    Completed

    Status: Active Not Recruiting → Completed

  2. Mar 2020 — Jul 2020 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

  3. Feb 2020 — Mar 2020 [monthly]

    Recruiting

  4. Dec 2019 — Feb 2020 [monthly]

    Recruiting

  5. Nov 2019 — Dec 2019 [monthly]

    Recruiting

  6. Oct 2019 — Nov 2019 [monthly]

    Recruiting

  7. Sep 2019 — Oct 2019 [monthly]

    Recruiting

  8. Aug 2019 — Sep 2019 [monthly]

    Recruiting

  9. Jun 2019 — Aug 2019 [monthly]

    Recruiting

  10. May 2019 — Jun 2019 [monthly]

    Recruiting

  11. Apr 2019 — May 2019 [monthly]

    Recruiting

    Status: Not Yet Recruiting → Recruiting

  12. Mar 2019 — Apr 2019 [monthly]

    Not Yet Recruiting

  13. Dec 2018 — Mar 2019 [monthly]

    Not Yet Recruiting

  14. Oct 2018 — Dec 2018 [monthly]

    Not Yet Recruiting

  15. Sep 2018 — Oct 2018 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Al Mansurah, Egypt , Alexandria, Egypt , Asyut, Egypt , Behira, Egypt , Cairo, Egypt , El Rehab, Egypt , Fiasal, Egypt , Giza, Egypt , Haram, Egypt , Heliopolis, Egypt and 10 more locations